Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate: A Randomized, Open-Label Phase 2 Study.

Attard G, et al. JAMA Oncology. 2019

https://jamanetwork.com/journals/jamaoncology/fullarticle/2737089

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.

Conteduca V, et al. European Urology. 2018.

https://www.europeanurology.com/article/S0302-2838(18)30739-5/fulltext

Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test.

Jayaram A, Wetterskog D, Attard G, Cancer Discov. 2018.

http://cancerdiscovery.aacrjournals.org/content/8/4/392.long

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.

Conteduca V, et al. Ann Oncol. 2017.

https://academic.oup.com/annonc/article/28/7/1508/3792654

Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.

McDaniel AS, et al. BJU Int. 2017.

https://onlinelibrary.wiley.com/doi/abs/10.1111/bju.13631

Plasma AR and abiraterone-resistant prostate cancer.

Romanel A, et al. Sci Transl Med. 2015

http://stm.sciencemag.org/content/7/312/312re10.full

Sequencing of agents in castration-resistant prostate cancer.

Lorente D, et al. Lancet Oncol. 2015

https://www.sciencedirect.com/science/article/pii/S1470204515700331?via%3Dihub

Androgen receptor expression in circulating tumour cells from castratio0resistant prostate cancer patients treated with novel endocrine agents.

Crespo M, et al. Br J Cancer. 2015

https://www.nature.com/articles/bjc201563

Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

Attard G, et al. Clin Cancer Res. 2015

http://clincancerres.aacrjournals.org/content/21/7/1621.long

Tumor clone dynamics in lethal prostate cancer.

Carreira S, et al. Sci Transl Med. 2014

http://stm.sciencemag.org/content/6/254/254ra125.full

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

Richards J, et al. Cancer Res. 2012

http://cancerres.aacrjournals.org/content/72/9/2176

Selected publications

Treatment Resistance Group, UCL Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6DD, UK

  • Twitter Clean Grey